Biogen is buying anti-inflammatory drug startup RayThera for up to $1 billion
The deal adds multiple small-molecule anti-inflammatory drug candidates to Biogen's pipeline, with the lead asset set to begin human trials this summer
点赞
收藏
点踩
分享评论
?
参与讨论
The deal adds multiple small-molecule anti-inflammatory drug candidates to Biogen's pipeline, with the lead asset set to begin human trials this summer